Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Zai Lab Limited is a Cayman-based holding company with substantial operations in mainland China, focused on discovering, developing, and commercializing innovative therapies in oncology, immunology, neuroscience, and infectious disease. It markets seven commercial programs across Greater China, including ZEJULA for ovarian cancer, VYVGART for generalized myasthenia gravis, NUZYRA for serious infections, OPTUNE for brain tumors, QINLOCK for advanced GIST, XACDURO for resistant Acinetobacter infections, and AUGTYRO for ROS1+ lung cancer and NTRK+ solid tumors.
The company has built a broad pipeline through internal R&D and global partnerships, highlighted by its DLL3-targeting ADC Zoci in late-stage development for small cell lung cancer and multiple autoimmune and kidney disease programs. Zai Lab emphasizes that it is not a Chinese operating company but a Cayman holding structure whose investors do not hold direct stakes in its Chinese subsidiaries.
The filing details extensive legal and operational risks tied to China, including evolving data, cybersecurity, anti-corruption and securities regulations, the need for multiple Chinese approvals and permissions, potential changes in U.S.–China relations, and constraints on capital raising and data transfers. Zai Lab also outlines its reliance on licenses from global pharma partners, use of Chinese and global contract manufacturers and CROs, and heavy dependence on Chinese government reimbursement systems such as the National Reimbursement Drug List and centralized hospital procurement.
Zai Lab Limited reported strong growth for the fourth quarter and full year 2025 while narrowing losses. Total revenue reached
Product revenue rose to
The company ended 2025 with
RTW Investments and Roderick Wong filed a Schedule 13G reporting beneficial ownership of 69,590,320 ordinary shares of Zai Lab Limited, equal to 6.3% of the class. The ownership is held through RTW-managed funds, with RTW and Dr. Wong sharing voting and dispositive power over these shares.
The percentage is based on 1,105,937,600 ordinary shares outstanding as of October 31, 2025, as disclosed in Zai Lab’s Form 10-Q. The filing notes that each American Depositary Share represents ten ordinary shares and states the position is held in the ordinary course of business, not for the purpose of influencing control of the company.
Qiming-related investment entities have filed an amended Schedule 13G reporting their ownership in Zai Lab Limited’s ordinary shares. QM11 Limited is shown as directly holding 48,883,643 ordinary shares, equal to 4.4% of the class, based on 1,119,628,030 shares outstanding as of December 31, 2025.
Those 48,883,643 ordinary shares consist of 280,680 American depositary shares and 46,076,843 ordinary shares. Qiming Venture Partners IV, L.P. is reported with shared beneficial ownership of 47,387,408 shares, or 4.2% of the class, while Qiming Managing Directors Fund IV, L.P. reports 1,496,235 shares, or 0.1%. The filing states that the reporting persons’ holdings represent ownership of 5 percent or less of the outstanding ordinary shares.
Capital World Investors, a division of Capital Research and Management Company and its affiliates, reports beneficial ownership of 1,723,600 shares of Zai Lab Ltd. common stock. This represents 0.2% of the 1,119,628,030 shares it believes are outstanding.
The firm has sole voting and dispositive power over these shares and no shared power. It states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Zai Lab, and that it owns less than five percent of the class.
Wellington Management Group LLP and related entities reported their beneficial ownership of Zai Lab Ltd. common stock on an amended Schedule 13G. They disclose beneficial ownership of 48,112,590 shares, representing 4.3% of the outstanding common stock, with no sole voting or dispositive power.
The filing states that all securities are held in the ordinary course of business for advisory clients of Wellington’s investment advisers. It also certifies that the holdings were not acquired, and are not held, for the purpose of changing or influencing control of Zai Lab.
FMR LLC and Abigail P. Johnson reported their beneficial ownership of Zai Lab Ltd common stock on an amended Schedule 13G. They disclosed beneficial ownership of 43,535,993 shares, representing 3.9% of the outstanding common stock as of December 31, 2025.
FMR LLC reported sole voting and dispositive power over these shares, while Abigail P. Johnson reported sole dispositive power but no voting power. The securities are described as being held in the ordinary course of business, without the purpose or effect of changing or influencing control of Zai Lab.
Zai Lab Ltd's Chief Legal Officer, identified as an officer of the company, reported an open-market sale of company stock. On 12/16/2025, the reporting person sold 8,651 American Depositary Shares (ADS) of Zai Lab at a price of $17.14 per ADS, as shown in Table I with transaction code "S" for a sale.
After this transaction, the reporting person beneficially owns 19,086 ADS, held directly. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The filing notes that this sale was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, indicating the trade was pre-arranged under that plan.
Zai Lab Ltd disclosed insider share movements by its chairperson and CEO, who is also a director. On December 10, 2025, the insider made a bona fide gift of 303,378 American Depositary Shares (ADSs) at a reported price of $0, leaving 586,641 ADSs beneficially owned afterward. On December 11, 2025, the insider received 377,520 ADSs, also at $0, as an annuity payment from the same grantor retained annuity trust, increasing beneficial ownership to 964,161 ADSs. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible.
Zai Lab Ltd (ZLAB) reported an insider stock sale by its Chief Legal Officer. On 11/21/2025, the officer sold 14,328 American Depositary Shares (ADS) of Zai Lab in an open-market transaction coded as an "S" sale at a price of $19.78 per ADS. After this transaction, the officer beneficially owned 27,737 ADS, held directly.
Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible. The filing notes that the trade was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 11/22/2024, indicating it was pre-arranged under that rule’s affirmative defense framework.